2nd Jan 2007 09:47
Acambis PLC02 January 2007 Holding in Company Cambridge, UK and Cambridge, Massachusetts - 2 January 2007 - Acambis plc("Acambis") (LSE: ACM, NASDAQ: ACAM) announces that it received notification on22 December 2006 that as from 19 December 2006 Barclays PLC no longer held anotifiable interest in the share capital of Acambis. -ends- Enquiries: Acambis plcElizabeth Brown, Company Secretary Tel: +44 (0) 1223 275 300 Lyndsay Wright, VP, Communications and Investor Relations About AcambisAcambis is a leading biotechnology company targeting infectious diseases withnovel vaccines. Acambis' development-stage pipeline includes vaccines that couldeither offer improvements over existing products or target unmet medical needs.As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developedin association with St Louis University, has also been used to developChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making itthe most advanced investigational vaccine against the West Nile virus. Acambisalso has the only vaccine in development against Clostridium difficile bacteria,a leading cause of hospital-acquired infections. Recognised internationally asthe leading producer of smallpox vaccines, Acambis is developing aninvestigational smallpox vaccine, ACAM2000, and is manufacturing emergency-usestockpiles of this investigational vaccine for the US Government and othergovernments around the world. Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and islisted on the London Stock Exchange (ACM). More information is available atwww.acambis.com. "Safe Harbor" statement under the Private Securities Litigation Reform Act of1995:The statements in this news release that are not historical facts areforward-looking statements that involve risks and uncertainties, including thetiming and results of clinical trials, product development, manufacturing andcommercialisation risks, the risks of satisfying the regulatory approval processin a timely manner, the need for and the availability of additional capital. Fora discussion of these and other risks and uncertainties see "Risk management" inthe Company's 2005 Annual Report and "Risk factors" in its Form 20-F, inaddition to those detailed on the Company's website and in the Company's filingsmade with the Securities and Exchange Commission from time to time. Theseforward-looking statements are based on estimates and assumptions made by themanagement of Acambis and are believed to be reasonable, though are inherentlyuncertain and difficult to predict. Actual results or experience could differmaterially from the forward-looking statements. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Barclays